anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Cerebral autoregulation (CA) is the ability of cerebral vascular system to contract or diastole with the change of perfusion pressure, and to maintain the stability of cerebral blood flow. It has been found that there are different degrees of CA damage in patients with traumatic brain injury, ischemic stroke, hemorrhagic stroke, aneurysmal subarachnoid hemorrhage, ischemic hypoxic encephalopathy and sepsis. At the same time, studies have shown that CA damage or loss is related to brain dysfunction and poor prognosis in patients with neurocritical diseases. Therefore, early assessment and intervention of CA can help identify individuals with high risk of complications and improve outcome.

Targeted temperature management (TTM) is a kind of body temperature management started when the core temperature of patients is higher than 37.5 ℃, including achieve hypothermia (TTMhypo) and maintain normal temperature (TTMnorm). TTMhypo has been widely considered as one of the neuroprotective therapies for a variety of brain diseases and injuries, including ischemic stroke, traumatic brain injury, hypoxic brain injury caused by out-of-hospital cardiac arrest and neonatal hypoxic ischemic encephalopathy. Its neuroprotective effects in reducing brain edema, reducing intracranial pressure, reducing brain metabolism and inhibiting apoptosis have been recognized. However, the existing studies mainly focus on the effect of TTMhypo on the mortality and neurological outcome of patients with severe neurological diseases in ICU. There is no large clinical study on the effect of targeted temperature management (TTM) on cerebral autoregulation in patients with severe neurological diseases. Due to the controversy of TTMhypo on mortality and neurological outcome, this study aime to reduce the patient's core temperature to normal. Patients with severe neurological disorders who still had cerebral autoregulation dysfunction, had fever, and needed to reduce the core temperature to normal. Therefore, the effect of TTMnorm on cerebral autoregulation before and during cooling was observed.The main measures were the THRR, Mx and TOx during cooling.
FIELD: medicine. ^ SUBSTANCE: invention refers to medicine, namely to surgery, and can be used for post-surgical treatment of the patients after an intestinal obstruction surgery. That is ensured by the diversional therapy. It is added with the intravenous drop-by-drop introduction of ozonised physiologic saline of ozone concentration 5mg/l in amount 200 ml for the first seven postoperative days once a day. ^ EFFECT: reduced time of enteroparesis relief with higher physiological value of the treatment and extended range of products for enteroparesis relief in such patients. ^ 2 tbl
0.05 to 0.8 parts by weight of a disinfectant for the mouth and/or throat are present in or on a matrix which contains 100 parts by weight of chewing gum base, and/or in a sugar coating enveloping the matrix. A pharmaceutical preparation of this type is used, inter alia, for preventing plaque formation. Particularly suitable as disinfectant is cetylpyridinium chloride. Additionally present in the matrix are, preferably 2 to 15 parts by weight of a lipoid substance and/or 5 to 20 parts by weight of a disintegrant on which the disinfectant is preferably applied or distributed. To produce this chewing gum, milled chewing gum base is mixed with powder particles of at least one additive which are coated with fats and/or waxes, with cooling. 0.05 to 0.8 parts by weight of a disinfectant are added to the mixture and/or to a sugar coating covering it. Subsequently tablets are compressed in cooled equipment.
Patients undergo leukapheresis on day -30 and receive lymphodepleting chemotherapy on days -10 to -3 per SOC on study. Patients then receive CMV-specific CD19-CAR T cells IV on day 0 and CMV-MVA triplex vaccine IM on days 28 and 56 in the absence of unacceptable toxicity on study. Patients also undergo x-ray during screening and on study, as well as PET, CT, MRI, blood sample collection, and bone marrow biopsy on study and during follow-up.
Cigarette smoking is a causative factor in the development of coronary heart disease (CHD), and is the most dangerous form of tobacco use. Effective treatments for smoking cessation exist but relapse to cigarette smoking is common, principally due to nicotine addiction and related symptoms of withdrawal. Little is known about how best to support smokers who have relapsed in subsequent attempts to change their smoking behavior. One emerging treatment has features that might make it appealing to smokers and may be effective in the setting of recent relapse: cytisine.

Cytisine is a plant-based smoking cessation medication with more than 50 years of use in central/eastern Europe. Cytisine is a partial agonist of nicotinic acetylcholine receptors (nAChRs), which is central to the effect of nicotine on the reward pathway. Cytisine acts by reducing the rewarding effect of nicotine and attenuating nicotine withdrawal symptoms. A recent review concluded that cytisine is the most promising future smoking cessation treatment. Cytisine is inexpensive to produce and is currently priced much lower than other cessation medications. It is well-tolerated by smokers and requires a shorter treatment period (i.e. 25 days) than conventional treatments. Because it is plant-based, cytisine may be attractive for smokers who prefer 'natural' medicines. Numerous placebo-controlled studies have demonstrated the safety and efficacy of cytisine. One high-quality pragmatic non-inferiority trial (n = 1310) found that cytisine was superior to nicotine replacement therapy (NRT) in improving self-reported continuous abstinence rates at 1 week, and 1, 2 and 6 months when both groups received minimal behavioural support. In Canada, cytisine is marketed as the natural health product Cravv™.

The long-term goal is to conduct a definitive, large-scale randomized controlled trial (RCT) of the efficacy of cytisine compared to conventional treatment (i.e. combination NRT) for smoking cessation among smokers who have relapsed to smoking following hospitalization for a CHD-related event. Prior to conducting a larger, definitive RCT there is a need to conduct a pilot study to better understand the potential feasibility of such a trial.
B. pertussis cells, are grown on a suitable conventional medium, are harvested by centrifugation, resuspended in cold distilled water, and then ruptured by explosive decompression in a cell fractionater by extrusion under a pressure of 15,000 to 50,000 p.s.i., through a small orifice, into a decompression chamber containing low-pressure nitrogen at 20 DEG C. or less.  The cells may also be ruptured by sonic oscillation or a mechanical mill.  The cell fractionater is sterilized before use by ethylene oxide gas and b -propiolactone. The cellular material is drained into a cooled receiver, and cell wall material sedimented by centrifugation, washed free from cell contents, and treated with deoxycholic acid solution to prepare a vaccine.  The initial whole cell harvest may be stored before use, after freezing, freeze drying, or being killed with thimerosal.ALSO:Antigenic material, for use in preparation of vaccine for B pertussis, is extracted from isolated B. pertussis cell wall material by treatment with a solution of sufficient deoxycholic acid salt to give a final concentration of 0.1 to 10% wt./vol., at 2 to 5 DEG C. and alkaline pH of a cell wall suspension equivalent to 100 to 2000 bacteria/ml.  The cells may be grown on conventional media, and ruptured mechanically, (see Division C6), and are then washed free from cellular material, extracted as above, the deoxycholate removed by, e.g. dialysis ion exchange, or ultra-filtration, and the solution used to prepare vaccines. These may be mono- or polyvalent, the latter containing toxoids such as Tetanus or Diptheria toxoid, or may be adsorbed onto adjuvants such as aluminium hydroxide or phosphate, or precipitated with alum.  The vaccines may contain preservatives such as thimerosal, benzethonium chloride, benzyl alcohol, or g -picolonium chloride.
Healthy Caucasian participants will receive EA1080 on Days 1 8 and 15 in selected formulations (Formulation E in fasted state, Formulation F in fasted state, Formulation F in fed state). These formulations will be tested in a crossover design. The order will be dependent on the treatment sequence in which participants will be allocated to treatment. A washout period of 6 days will be maintained between the dosing days of each treatment periods.
BACKGROUND: The purpose of dermal substitutes is to mimic the basic properties of the extracellular matrix of human skin. The application of dermal substitutes to the defect reduces the formation of hypertrophic scars and improves the scar quality. This study aims to develop an original dermal substitute enriched with stable fibroblast growth factor 2 (FGF2-STAB®) and test it in an animal model.
METHODS: Dermal substitutes based on collagen/chitosan scaffolds or collagen/chitosan scaffolds with nanofibrous layer were prepared and enriched with FGF2-STAB® at concentrations of 0, 0.1, 1.0, and 10.0 µg ‧ cm-2. The performance of these dermal substitutes was tested in vivo on artificially formed skin defects in female swine. The outcomes were evaluated using cutometry at 3 and 6 months. In addition, visual appearance was assessed based on photos of the scars at 1-month, 3-month and 6-month follow-ups using Yeong scale and Visual Analog Scale.
RESULTS: The dermal substitute was fully integrated into all defects and all wounds healed successfully. FGF2-STAB®-enriched matrices yielded better results in cutometry compared to scaffolds without FGF2. Visual evaluation at 1, 3, and 6 months follow-ups detected no significant differences among groups. The FGF2-STAB® effectiveness in improving the elasticity of scar tissues was confirmed in the swine model. This effect was independently observed in the scaffolds with nanofibres as well as in the scaffolds without nanofibres.
CONCLUSION: The formation of scars with the best elasticity was exhibited by addition 1.0 µg ‧ cm-2of FGF2-STAB® into the scaffolds, although it had no significant effect on visual appearance at longer follow-ups. This study creates the basis for further translational studies of the developed product and its progression into the clinical phase of the research.
Avoid duplicating information that will be entered elsewhere, such as Eligibility Criteria or Outcome Measures.

The data were collected by the researcher in the diabetes outpatient clinic where there is a sink for handwashing and a suitable area and equipment for blood collection. The researcher interviewed the patients who applied to the diabetes outpatient clinic, informed them about the study and obtained their written consents. After obtaining their written consents, the information of the patients was recorded in the Patient Identification Form. Then, the patients were informed about the use of the Visual Analog Scale. First, venous blood samples of the patients were collected into a tube by the researcher, and then their capillary blood samples were taken. A randomization scheme was created via the website https://www.randomizer.org/ in order to prevent bias during the evaluation of the pain felt due to drawing of capillary blood. According to this randomization order, patients were randomly assigned to one of the two groups. For capillary blood glucose measurement, two regions, fingertip and palm were used in every patient. In the first group, capillary blood glucose samples were taken first from the fingertip and then from the palm, and in the second group the capillary blood sample was first obtained from the palm and then the fingertip, and blood glucose measurements were made with the glucometer. The patient washed his/her hands with warm water and soap and dried them with a paper towel. Prior to capillary blood collection, the patient washed his/her hands with warm water, kept his hand below the level of the heart, waved downwards and gently massaged his/her fingertips in order to obtain appropriate amount of blood. The dominant hands of the patients were used to collect capillary blood samples. In order not to affect the research results, the same glucometer device was used for all capillary glucose measurements and a new 28G sterile lancet was used in each application. Between capillary blood glucose measurements, an average of 5 minutes was waited for pain assessment with VAS. In order to ensure the objectivity of the study, the nurse, who was trained by the researcher on the use of VAS before the study, evaluated the patient's pain at the end of each capillary blood glucose measurement by using VAS.
Since valproic acid has been associated with certain types of birth defects, female patients of childbearing age considering the use of valproic acid should be advised of the risk and of alternative therapeutic options and to read the , which appears as the last section of the labeling. Patient Information LeafletThis is especially important when the treatment of a spontaneously reversible condition not ordinarily associated with permanent injury or risk of death (e.g., migraine) is considered.

Patients should be encouraged to enroll in the North American Antiepileptic Drug (NAAED) Pregnancy Registry if they become pregnant. This registry is collecting information about the safety of antiepileptic drugs during pregnancy. To enroll, patients can call the toll free number 1-888-233-2334 (see ). PRECAUTIONS - Pregnancy

Patients and guardians should be warned that abdominal pain, nausea, vomiting, and/or anorexia can be symptoms of pancreatitis and, therefore, require further medical evaluation promptly.
Participants will receive eight scheduled phone contacts from a peer counselor. Two are prenatal and 6 are postpartum.
Patients with SBS will be initiated on green bean purees added to enteral formula recipes, based on kilocalories of enteral formula over 3 weeks. During week 1 subjects will prepare and add 50 mL green bean puree per 1000kcal of enteral feed (5%) to their formula mixture, increasing to 100ml (10%) and 150ml (15%) during weeks 2 and 3, respectively.
Enrolled subjects were treated with Cocktail substrate (Midazolam, dextromethorphan, Rosuvastatin and digoxin) on an empty stomach on Day 1. JMKX001899 was administered orally once daily after a standardized meal from Day 9 to Day 20 and Day 22. Cocktail and JMKX001899 were administered simultaneously on an empty stomach on Day 8 and Day 21.
Patients receive decitabine IV over 1 hour on days 1-10, quizartinib PO every day beginning on day 1 of cycle 1, and venetoclax PO on days 1-14 (days 1-21 if persistent leukemia). Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Stable solid gefarnate compds. were prepd. by mixing gefarnate with antacid Al complds. or Mg compds., e.g., meta magnesium aluminosilicate, magnesium silicate or dry hydroxide gel which was treated with mono saccharides, disaccharides or sugar alcs. to control pka(<=9.3) at its surface.  Thus, 150 g lactose dissolved in 480g H2O, was mixed with 300 g meta magnesium aluminosilicate and dried at 60oC for 17 hr in traydrier.  The obtained powder 500 g was blended with 50g gefarnate to give a powdered product.
The study will provide PK, safety, tolerability and efficacy data collected during 48 weeks of treatment with deferasirox in Chinese pediatric patients with transfusion dependent -thalassemia major, aged 2 to \<6 years at enrollment. The target patient pool consists of 20 patients with evidence of iron overload measured by serum ferritin level at the start of study. Patients will start their deferasirox treatment with a dose of 20 mg/kg/day. Serum ferritin will be monitored every month and the dose of deferasirox will be adjusted if necessary every 3 months based on the trends in serum ferritin. Other possible dose adjustments will be based on the patient's safety assessments.
The invention provides a pharmaceutical composition and a method for treating cancer, and the composition comprises a proteasome inhibitor and a nuclear export inhibitor. The composition has synergistic effects on treating cancers, particularly a solid tumor cancer. Specifically, the proteasome inhibitor bortezomib and CRM1 inhibitor KPT330 induce apoptosis and cell cycle arrest in sensitive cells, such as HCT116 and RKO cells. Bortezomib induces the nuclear export of p53, whereas it could be effectively blocked by KPT330. CRM1 inhibitor KPT330 synergistically sensitizes CRC cells to bortezomib treatment in vitro and in vivo, through inhibiting nuclear export and restoring functions of p53. The invention also provides use of proteasome inhibitor in a solid tumor cancer. The invention provides a rationale for the use of proteasome inhibitor together with nuclear export blocker in the treatment of cancers, such as colorectal cancer.
This study utilizes a conventional phase I study design with a '3+3 cohort expansion' design(15), to determine the MTD of 1) Cabazitaxel, in Part A, and 2) Radiotherapy, in Part B. The determination of the MTD is given in Section 5.2, Definition of Dose - Limiting Toxicity. All patients who enter the study, and begin concurrent chemo-radiation are analyzable for the primary endpoint of the study.
The invention relates to construction of a BCG vaccine through chimeric expression of GMCSF-CFP10-ESAT6 protein with a human GM-CSF gene, and a CFP10 gene and an ESAT6 gene of mycobacterium tuberculosis and research on immunogenicity of the BCG vaccine. In the construction method, a human GM-CSF gene sequence and a CFP10 gene sequence and an ESAT6 gene sequence of the mycobacterium tuberculosis are inserted into one escherichia coli-mycobacterium tuberculosis shuttle plasmid pMV361 sequence through the genetic engineering technology to construct a recombinant shuttle plasmid rpMV361GMCSF-CFP10-ESAT6. Then the carrier is guided into a BCG vaccine through electroporation to construct a recombinant BCG vaccine rBCG: GMCSF-CFP10-ESAT6. The recombinant BCG vaccine constructed in the invention can stably express the GMCSF-CFP10-ESAT6 chimeric protein, and the immunogenicity of the recombinant BCG vaccine is superior to that of the immunogenicity of the traditional BCG vaccine. The invention also provides a preparation process of the recombinant BCG vaccine and research on the immunity of the recombinant BCG vaccine, which belong to the genetic engineering field and the tuberculosis vaccine field. Moreover, the invention can prevent the occurrence and spread of the tuberculosis more effectively.
This cohort comprises 10,308 British civil servants (6,895 men and 3,413 women). The cohort study commenced data collection in 1985 and participants have since undergone questionnaire and clinical assessments across regular intervals. Additional tracking of health outcomes has been performed through linkage with administrative databases. Demographic, behavioural and clinical data will be sourced from this cohort for the purposes of the current study.
BACKGROUND: Acromial stress fractures following reverse shoulder arthroplasty (RSA) have gained attention among specialized surgeons over the past decades craving answers regarding predisposing factors and technical aspects as how to avoid the complication. This study introduces the acetabularization index (AI) for the preoperative estimation of acromial bone loss attributed to acetabularization in cases of cuff tear arthropathy (CTA).
METHODS: The acromiohumeral interval (AHI), extent of acromial acetabularization (AA), acromial height (AH), and width of acetabularization (r) were measured on preoperative radiographs and two-dimensional computed tomography scans (2D CT) of patients who underwent RSA within the timeline 2019-2023 for CTA. The AI calculated  AI % = AA mm ÷ AH mm    . The CTA grade was determined according to the Hamada classification. The AI values on radiographs and 2D CT were compared by a Student's t-test. Possible correlation between the AI and AHI was investigated via Pearson's coefficient. The intraclass correlation coefficient (ICC) was employed to test the interobserver reliability among two independent testers.
RESULTS: The radiographs and 2D CT scans of thirty-three patients who underwent RSA were analyzed. The mean AHI, AH, AA, r, and AI values on radiographs were 5.5 ± 2 mm, 10 ± 2 mm, 2 ± 2 mm, 30 ± 4 mm, 16 ± 16%, respectively. On 2D CT, the corresponding mean values were 4.7 ± 2.5 mm, 10.8 ± 2.65 mm, 2.45 ± 2.35 mm, and 30 ± 4.5, and 22.3 ± 22%, respectively. There was a statistically significant difference between the AI values on radiographs and 2D CT (P = .000). The Pearson's correlation coefficient demonstrated a negative correlation between AI and AHI (r = - 0.33). Excellent reliability was observed by the ICC values for all parameters in both groups among two testers.
CONCLUSION: The AI is a reliably measurable tool on radiographs and 2D CT scans; however, the measurements derived from radiographs vary significantly from CT based measurements due to projection restrictions. Grade IVB of the Hamada/Fukuda classification is associated with the highest AI values. Further research is warranted to assess the clinical utility of this index as a predictive tool for postoperative acromial stress fractures.
All participants will participate in a modified Cycles approach where speech targets are worked on for a short period of time and switched within a cycle. During the Harder Targets arm, children will work on target sounds that are "harder" based on their pre-treatment scores of 15, 14, 13, or 12 on the Glaspey Dynamic Assessment of Phonology. Children will complete 8 sessions in this arm that are each 50-minutes long and occur two times per week with each target addressed for 2 sessions.
The invention relates to the chemical, pharmaceutical and food industries and may be used in the production of nonalcoholic beverages and cosmetics having heightened antioxidant activity. A hydrogen cocktail, a means for stimulating lymphatic drainage, consists of drinking water which has undergone membrane cleaning and which is saturated, under pressure, with molecular hydrogen. The water then displays antioxidant activity and decreases to negative values of oxidation reduction potential. The aim of the present invention is to increase the antioxidant activity of a hydrogen cocktail without any undesirable irritating effects in humans. The aim is achieved by producing a hydrogen cocktail in the form of a water composition having molecular hydrogen dissolved therein under pressure and a small concentration of a food additive, an antioxidant, additionally dissolved therein. The composition provides a synergistic effect as evidenced by a manyfold increase in the antioxidant activity of the hydrogen cocktail. The hydrogen cocktail may be produced in the form of a bottled nonalcoholic beverage, and in the form of an antioxidant cosmetic in aerosol canisters where the gas propellant is hydrogen. The increased antioxidant activity of the hydrogen cocktail imparts a higher quality and physiological value to same. The high reduction potential makes the water of the hydrogen cocktail "come alive".